https://doi.org/10.4081/aiua.2024.12104

Revolutionizing localized prostate cancer treatment: Stereotactic radiotherapy “Moroccan experience”

Vol. 96 No. 1 (2024)
Submitted: November 17, 2023
Accepted: December 23, 2023
Published: February 16, 2024
Localized prostate cancer, stereotactic radiotherapy, toxicity, efficacy
Abstract Views: 358
PDF: 230
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Asmâa Naim
doc.a.naim@gmail.com
Faculty of Medicine, Mohammed VI University of Sciences and Health, Casablanca; Research Unit, Mohammed VI Center for Research and Innovation, Rabat; Radiotherapy Department of Casablanca Cancer Center, University International Hospital Cheikh Khalifa, Casablanca, Morocco.
Zineb Lahlou
Faculty of Medicine, Mohammed VI University of Sciences and Health, Casablanca; Research Unit, Mohammed VI Center for Research and Innovation, Rabat, Morocco.
Othmane Kaanouch
Radiotherapy Department of Casablanca Cancer Center, University International Hospital Cheikh Khalifa, Casablanca; Hassan First University of Settat, High Institute of Health Sciences, Laboratory of Sciences and Health Technologies, Settat, Morocco.
Abdelajalil Heddat
https://orcid.org/0000-0002-3725-9070
Faculty of Medicine, Mohammed VI University of Sciences and Health, Casablanca; Research Unit, Mohammed VI Center for Research and Innovation, Rabat; Urology Department, University International Hospital Cheikh Khalifa, Casablanca, Morocco.
Safae Mansouri
Faculty of Medicine, University Hassan II, Casablanca, Morocco.

Introduction: Prostate cancer is the most common urological cancer, and its incidence  is increasing. Radical prostatectomy and radiotherapy are theprimary treatments for localized forms. Stereotactic Body RadioTherapy (SBRT), a new and innovative therapy, has been validated for some cancer localizations but not yet for localized prostate cancer. Our study aims to report the efficacy and tolerance results of SBRT for localized prostate cancer.
Materials and methods: This is a retrospective study of 27 patients with localized prostate cancer (CaP) who were treated with SBRT in our department from 2017 to 2021 using transponders for tumor tracking. The dose was 36.25 Gy delivered in five fractions of 7.25 Gy. The delineation and doses of organs at risk were determined based on the recommendations of the SFRO and the TG101 report of medical physics. All patients were treated using a latest-generation linear accelerator (True Beam STXÒ).
Results: Acute toxicities were observed in 33.3% of cases, with 22.2% grade 1 or 2 genitourinary (GU) and no grade 3 while 11.1% gastrointestinal (GI) toxicities were reported as grade 1-2 (7.4%) and one case grade 3 (3.7%). Late grade 1 or 2 GU toxicity was observed in 14.84% of cases, with no reports of late GI toxicity. After a 26-month follow-up period, the biochemical failure-free survival rate was 92.6%.
Conclusions: The results of our study are consistent with the existing literature and support the safety and effectiveness of SBRT as a treatment option for localized prostate cancer (CaP). In the United States, both ASTRO and the NCCN recognize SBRT as a valid treatment option for localized CaP. Ongoing phase III trials are being conducted to further substantiate these long-term results and to establish SBRT as the future standard of care for localized CaP.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209-49. DOI: https://doi.org/10.3322/caac.21660
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017; 67:7-30. DOI: https://doi.org/10.3322/caac.21387
Langrand-Escure J, de Crevoisier R, Llagostera C, et al. Dose constraints for moderate hypofractionated radiotherapy for prostate cancer: The French genito-urinary group (GETUG) recommendations. Cancer/Radiothérapie. 2018; 22:193-8. DOI: https://doi.org/10.1016/j.canrad.2017.11.004
Wilke L, Andratschke N, Blanck O, et al. ICRU report 91 on prescribing, recording, and reporting of stereotactic treatments with small photon beams. Strahlenther Onkol. 2019;195:193-8. DOI: https://doi.org/10.1007/s00066-018-1416-x
Noël G, Antoni D, Barillot I, Chauvet B. Délinéation des organs à risque et contraintes dosimétriques. Cancer/Radiothérapie. 2016;20:S36-60. DOI: https://doi.org/10.1016/j.canrad.2016.07.032
Freites-Martinez A, Santana N, Arias-Santiago S, Viera A. Using the Common Terminology Criteria for Adverse Events (CTCAE -SSRB5 Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies. Actas Dermosifiliogr (Engl Ed) 2021;112:90-2. DOI: https://doi.org/10.1016/j.adengl.2019.05.021
Roach M, Hanks G, Thames H, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65:965-74. DOI: https://doi.org/10.1016/j.ijrobp.2006.04.029
Fowler J, Chappell R, Ritter M. Is alpha/beta for prostate tumors really low? Int J Radiat Oncol Biol Phys. 2001;50:1021-31. DOI: https://doi.org/10.1016/S0360-3016(01)01607-8
Leborgne F, Fowler J, Leborgne JH, Mezzera J. Later outcomes and alpha/beta estimate from hypofractionated conformal three-dimensional radiotherapy versus standard fractionation for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2012; 82:1200-7. DOI: https://doi.org/10.1016/j.ijrobp.2010.12.040
Brenner DJ, Martinez AA, Edmundson GK, et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low α/βratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys. 2002;52:6-13. DOI: https://doi.org/10.1016/S0360-3016(01)02664-5
Miralbell R, Roberts SA, Zubizarreta E, Hendry JH. Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: α/β = 1.4 (0.9-2.2) Gy. Int J Radiat Oncol Biol Phys. 2012;82:e17-24. DOI: https://doi.org/10.1016/j.ijrobp.2010.10.075
Avkshtol V, Dong Y, Hayes SB, et al. A comparison of robotic arm versus gantry linear accelerator stereotactic body radiation therapy for prostate cancer. Res Rep Urol. 2016;8:145-58. DOI: https://doi.org/10.2147/RRU.S58262
Zaorsky NG, Palmer JD, Hurwitz MD, et al. What is the ideal radiotherapy dose to treat prostate cancer? A meta-analysis of biologically equivalent dose escalation. Radiother Oncol. 2015;115:295-300. DOI: https://doi.org/10.1016/j.radonc.2015.05.011
Boustani J, Grapin M, Laurent PA, et al. The 6th R of Radiobiology: Reactivation of Anti-Tumor Immune Response. Cancers. 2019;11:860. DOI: https://doi.org/10.3390/cancers11060860
Dee EC, Muralidhar V, Arega MA, et al. Factors Influencing Noncompletion of Radiation Therapy Among Men With Localized Prostate Cancer. Int J Radiat Oncol Biol Phys. 2021;109:1279-85. DOI: https://doi.org/10.1016/j.ijrobp.2020.11.064
Lischalk JW, Kaplan ID, Collins SP. Stereotactic Body Radiation Therapy for Localized Prostate Cancer. Cancer J. 2016;22:307-13. DOI: https://doi.org/10.1097/PPO.0000000000000209
Meier RM, Bloch DA, Cotrutz C, et al. Multicenter Trial of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: Survival and Toxicity Endpoints. Int J Radiat Oncol Biol Phys. 2018;102:296-303. DOI: https://doi.org/10.1016/j.ijrobp.2018.05.040
Pan HY, Jiang J, Hoffman KE, et al. Comparative Toxicities and Cost of Intensity-Modulated Radiotherapy, Proton Radiation, and Stereotactic Body Radiotherapy Among Younger Men With Prostate Cancer. J Clin Oncol. 2018;36:1823-1830. DOI: https://doi.org/10.1200/JCO.2017.75.5371
Brand DH, Tree AC, Ostler P, et al. PACE Trial Investigators. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, noninferiority trial. Lancet Oncol. 2019; 20:1531-1543. DOI: https://doi.org/10.1016/S1470-2045(19)30569-8
Widmark A, Gunnlaugsson A, Beckman L, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet. 2019;394:385-95. DOI: https://doi.org/10.1016/S0140-6736(19)31131-6
Madsen BL, Hsi RA, Pham HT, et al. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys. 2007; 67:1099-105. DOI: https://doi.org/10.1016/j.ijrobp.2006.10.050
Jackson WC, Silva J, Hartman HE, et al. Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies. Int J Radiat Oncol Biol Phys. 2019;104:778-789. DOI: https://doi.org/10.1016/j.ijrobp.2019.03.051
Katz A. Stereotactic Body Radiotherapy for Low-Risk Prostate Cancer: A Ten-Year Analysis. Cureus. 2017;9:e1668. DOI: https://doi.org/10.7759/cureus.1668
Bian SX, Kuban DA, Levy LB, et al. Addition of short-term androgen deprivation therapy to dose-escalated radiation therapy improves failure-free survival for select men with intermediate-risk prostate cancer. Ann Oncol. 2012; 23:2346-52. DOI: https://doi.org/10.1093/annonc/mds001

How to Cite

Naim, A., Lahlou, Z., Kaanouch, O., Heddat, A., & Mansouri, S. (2024). Revolutionizing localized prostate cancer treatment: Stereotactic radiotherapy “Moroccan experience”. Archivio Italiano Di Urologia E Andrologia, 96(1). https://doi.org/10.4081/aiua.2024.12104
Copyright (c) 2024 the Author(s) Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.